219 related articles for article (PubMed ID: 36905581)
1. Costs of radium-223 and the pharmacy preparation
Quist SW; Paulissen JHJ; Wyndaele DNJ; Nagarajah J; Freriks RD
J Med Econ; 2023; 26(1):366-375. PubMed ID: 36905581
[TBL] [Abstract][Full Text] [Related]
2. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
3.
Rahbar K; Essler M; Eiber M; la Fougère C; Prasad V; Fendler WP; Rassek P; Hasa E; Dittmann H; Bundschuh RA; Pabst KM; Kurtinecz M; Schmall A; Verholen F; Sartor O
J Nucl Med; 2023 Dec; 64(12):1925-1931. PubMed ID: 37827838
[No Abstract] [Full Text] [Related]
4. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
6. PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects.
Parghane RV; Basu S
Expert Rev Anticancer Ther; 2023; 23(9):959-975. PubMed ID: 37565281
[TBL] [Abstract][Full Text] [Related]
7. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
8.
Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
[TBL] [Abstract][Full Text] [Related]
9. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
Ramnaraign B; Sartor O
Oncologist; 2023 May; 28(5):392-401. PubMed ID: 36806966
[TBL] [Abstract][Full Text] [Related]
10. AlphaBet: Combination of Radium-223 and [
Kostos L; Buteau JP; Yeung T; Iulio JD; Xie J; Cardin A; Chin KY; Emmerson B; Owen KL; Parker BS; Fettke H; Furic L; Azad AA; Hofman MS
Front Med (Lausanne); 2022; 9():1059122. PubMed ID: 36465905
[TBL] [Abstract][Full Text] [Related]
11. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
O'Sullivan JM; Abramowitz E; Sierra-Scacalossi L
Future Oncol; 2023 May; 19(15):1021-1028. PubMed ID: 36942803
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
13. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
14. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
Ahmadzadehfar H; Rahbar K; Baum RP; Seifert R; Kessel K; Bögemann M; Kulkarni HR; Zhang J; Gerke C; Fimmers R; Kratochwil C; Rathke H; Ilhan H; Maffey-Steffan J; Sathekge M; Kabasakal L; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):113-122. PubMed ID: 32383093
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Mehrens D; Kramer KKM; Unterrainer LM; Beyer L; Bartenstein P; Froelich MF; Tollens F; Ricke J; Rübenthaler J; Schmidt-Hegemann NS; Herlemann A; Unterrainer M; Kunz WG
J Natl Compr Canc Netw; 2023 Jan; 21(1):43-50.e2. PubMed ID: 36634610
[TBL] [Abstract][Full Text] [Related]
16. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
17. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
18. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
19. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging and biochemical response assessment after a single cycle of [
Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
